The Gut Microbiome and Treatment-Resistance in Schizophrenia

Overview

Journal Psychiatr Q

Specialty Psychiatry

Date 2019 Nov 30

PMID 31781943

Citations 6

Authors

Mary V Seeman

Affiliations

Soon will be listed here.

Abstract

The effect of antipsychotic medication is poor in 30-40% of patients with schizophrenia; treatment resistance is usually met with shifts to new drugs or drug augmentation strategies or a trial of clozapine. The purpose of this review was to examine the potential role of intestinal bacteria in the bioavailability of antipsychotic medication and the possibility that parenterally administered antipsychotics might be able to overcome treatment resistance. Databases were searched with appropriate terms to locate relevant papers dealing with the effect of antipsychotic drugs on the gut microbiome and the effect of bacterial metabolizing enzymes on antipsychotic drugs. Also searched were papers addressing the various current parenteral formulations of antipsychotic drugs. Sixty-five recent pertinent papers were reviewed and the results are suggestive of the premise that there is a drug refractory form of psychosis for which the composition of gut bacteria is responsible, and that parenteral drug administration could overcome the problem.

Citing Articles

Neuroinflammation and Schizophrenia: New Therapeutic Strategies through Psychobiotics, Nanotechnology, and Artificial Intelligence (AI).

Cruz Mosquera F, Guevara-Montoya M, Serna-Ramirez V, Liscano Y J Pers Med. 2024; 14(4).

PMID: 38673018 PMC: 11051547. DOI: 10.3390/jpm14040391.

Cytokine Imbalance as a Biomarker of Treatment-Resistant Schizophrenia.

Shnayder N, Khasanova A, Strelnik A, Al-Zamil M, Otmakhov A, Neznanov N Int J Mol Sci. 2022; 23(19).

PMID: 36232626 PMC: 9570417. DOI: 10.3390/ijms231911324.

Potential relationship between Tourette syndrome and gut microbiome.

Geng J, Liu C, Xu J, Wang X, Li X J Pediatr (Rio J). 2022; 99(1):11-16.

PMID: 35914739 PMC: 9875241. DOI: 10.1016/j.jped.2022.06.002.

Shedding light on biological sex differences and microbiota-gut-brain axis: a comprehensive review of its roles in neuropsychiatric disorders.

Shobeiri P, Kalantari A, Teixeira A, Rezaei N Biol Sex Differ. 2022; 13(1):12.

PMID: 35337376 PMC: 8949832. DOI: 10.1186/s13293-022-00422-6.

The Microbiota/Microbiome and the Gut-Brain Axis: How Much Do They Matter in Psychiatry?.

Marazziti D, Buccianelli B, Palermo S, Parra E, Arone A, Beatino M Life (Basel). 2021; 11(8).

PMID: 34440503 PMC: 8401073. DOI: 10.3390/life11080760.

References

Abdelbary A, Bendas E, Ramadan A, Mostafa D . Pharmaceutical and pharmacokinetic evaluation of a novel fast dissolving film formulation of flupentixol dihydrochloride. AAPS PharmSciTech. 2014; 15(6):1603-10. PMC: 4245445. DOI: 10.1208/s12249-014-0186-8. View

Ticinesi A, Milani C, Lauretani F, Nouvenne A, Mancabelli L, Lugli G . Gut microbiota composition is associated with polypharmacy in elderly hospitalized patients. Sci Rep. 2017; 7(1):11102. PMC: 5593887. DOI: 10.1038/s41598-017-10734-y. View

Park S, Choi M, Choi J, Park E, Tchoe H, Suh J . Comparative Efficacy and Safety of Long-acting Injectable and Oral Second-generation Antipsychotics for the Treatment of Schizophrenia: A Systematic Review and Meta-analysis. Clin Psychopharmacol Neurosci. 2018; 16(4):361-375. PMC: 6245299. DOI: 10.9758/cpn.2018.16.4.361. View

Zun L . Evidence-Based Review of Pharmacotherapy for Acute Agitation. Part 1: Onset of Efficacy. J Emerg Med. 2018; 54(3):364-374. DOI: 10.1016/j.jemermed.2017.10.011. View

Qin J, Li R, Raes J, Arumugam M, Burgdorf K, Manichanh C . A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010; 464(7285):59-65. PMC: 3779803. DOI: 10.1038/nature08821. View

Currier G, Walsh P . Safety and efficacy review of inhaled loxapine for treatment of agitation. Clin Schizophr Relat Psychoses. 2013; 7(1):25-32. DOI: 10.3371/CSRP.CUWA.032513. View

Schwarz E, Maukonen J, Hyytiainen T, Kieseppa T, Oresic M, Sabunciyan S . Analysis of microbiota in first episode psychosis identifies preliminary associations with symptom severity and treatment response. Schizophr Res. 2017; 192:398-403. DOI: 10.1016/j.schres.2017.04.017. View

Zhernakova A, Kurilshikov A, Bonder M, Tigchelaar E, Schirmer M, Vatanen T . Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science. 2016; 352(6285):565-9. PMC: 5240844. DOI: 10.1126/science.aad3369. View

Quintana D, Guastella A, Westlye L, Andreassen O . The promise and pitfalls of intranasally administering psychopharmacological agents for the treatment of psychiatric disorders. Mol Psychiatry. 2015; 21(1):29-38. DOI: 10.1038/mp.2015.166. View

10.

Hassan A, De Luca V . The effect of lifetime adversities on resistance to antipsychotic treatment in schizophrenia patients. Schizophr Res. 2014; 161(2-3):496-500. DOI: 10.1016/j.schres.2014.10.048. View

11.

Misawa F, Kishimoto T, Hagi K, Kane J, Correll C . Safety and tolerability of long-acting injectable versus oral antipsychotics: A meta-analysis of randomized controlled studies comparing the same antipsychotics. Schizophr Res. 2016; 176(2-3):220-230. DOI: 10.1016/j.schres.2016.07.018. View

12.

Al-Hilal T, Alam F, Byun Y . Oral drug delivery systems using chemical conjugates or physical complexes. Adv Drug Deliv Rev. 2012; 65(6):845-64. DOI: 10.1016/j.addr.2012.11.002. View

13.

Zimmermann M, Zimmermann-Kogadeeva M, Wegmann R, Goodman A . Separating host and microbiome contributions to drug pharmacokinetics and toxicity. Science. 2019; 363(6427). PMC: 6533120. DOI: 10.1126/science.aat9931. View

14.

Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson E . Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018; 555(7698):623-628. PMC: 6108420. DOI: 10.1038/nature25979. View

15.

Johnson C, Zhao C, Xu Y, Mori T . Timing the day: what makes bacterial clocks tick?. Nat Rev Microbiol. 2017; 15(4):232-242. PMC: 5696799. DOI: 10.1038/nrmicro.2016.196. View

16.

Kaminsky B, Bostwick J, Guthrie S . Alternate Routes of Administration of Antidepressant and Antipsychotic Medications. Ann Pharmacother. 2015; 49(7):808-17. DOI: 10.1177/1060028015583893. View

17.

Lieberman J, Stroup T, McEvoy J, Swartz M, Rosenheck R, Perkins D . Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353(12):1209-23. DOI: 10.1056/NEJMoa051688. View

18.

Barton W, Penney N, Cronin O, Garcia-Perez I, Molloy M, Holmes E . The microbiome of professional athletes differs from that of more sedentary subjects in composition and particularly at the functional metabolic level. Gut. 2017; 67(4):625-633. DOI: 10.1136/gutjnl-2016-313627. View

19.

Cussotto S, Clarke G, Dinan T, Cryan J . Psychotropics and the Microbiome: a Chamber of Secrets…. Psychopharmacology (Berl). 2019; 236(5):1411-1432. PMC: 6598948. DOI: 10.1007/s00213-019-5185-8. View

20.

Skonieczna-Zydecka K, Loniewski I, Misera A, Stachowska E, Maciejewska D, Marlicz W . Second-generation antipsychotics and metabolism alterations: a systematic review of the role of the gut microbiome. Psychopharmacology (Berl). 2018; 236(5):1491-1512. PMC: 6598971. DOI: 10.1007/s00213-018-5102-6. View